Literature DB >> 21840905

Expression of visfatin mRNA in peripheral blood mononuclear cells is not correlated with visfatin mRNA in omental adipose tissue in women with polycystic ovary syndrome.

Kok-Min Seow1, Jiann-Loung Hwang, Peng-Hui Wang, Low-Tone Ho, Chi-Chang Juan.   

Abstract

BACKGROUND: Visfatin, which is secreted predominantly from visceral adipose tissue, has an insulin-mimetic action and may play a role in the regulation of insulin sensitivity in humans. Peripheral blood mononuclear cells (PBMCs) from venous blood samples are the most accessible tissue for the analysis of gene expression. The aims of the study were to compare the expression of visfatin in PBMCs with that in omental adipose tissue in women with polycystic ovary syndrome (PCOS).
METHODS: Visfatin mRNA was measured in omental adipose tissue and PBMCs from 10 women with PCOS and 10 healthy controls, matched for BMI and age, using the real-time polymerase chain reaction (PCR).
RESULTS: The expression of visfatin mRNA in both omental adipose tissue and PBMCs from the women with PCOS was significantly higher (P = 0.01 and P = 0.05, respectively) than that in the controls. This finding indicated that mononuclear cells are a potential source of visfatin in women with PCOS. However, only the expression of visfatin mRNA in adipose tissue, not that in PBMCs, showed a significant positive correlation with insulin levels 2h after glucose loading (P = 0.044, r(2) = 0.45), and with homeostasis model assessment-insulin resistance (HOMA(IR); P = 0.035, r(2) = 0.47). In addition, the expression of visfatin mRNA in PBMCs did not correlate with the expression of visfatin mRNA in omental adipose tissue.
CONCLUSIONS: PCOS is associated with increased visfatin mRNA concentrations in PBMCs and in omental adipose tissue. However, only visfatin mRNA concentration in omental adipose tissue is closely correlated with BMI and insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840905     DOI: 10.1093/humrep/der267

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  6 in total

1.  Analysis of Changes in Serum Levels and Gene Expression Profiles of Novel Adipocytokines (Omentin, Vaspin, Irisin and Visfatin) and Their Correlation with Serum C-reactive Protein Levels in Women Diagnosed with Endometriosis

Authors:  Ecem Kaya Sezginer; Ömer Faruk Kırlangıç; Merve Didem Eşkin Tanrıverdi; Hasan Onur Topçu; Serap Gür
Journal:  Turk J Pharm Sci       Date:  2022-02-28

Review 2.  Polycystic Ovary Syndrome: Important Underrecognised Cardiometabolic Risk Factor in Reproductive-Age Women.

Authors:  Dinka Pavicic Baldani; Lana Skrgatic; Roya Ougouag
Journal:  Int J Endocrinol       Date:  2015-06-01       Impact factor: 3.257

3.  Visfatin and resistin serum levels in normal-weight and obese women with polycystic ovary syndrome.

Authors:  Fatemeh Farshchian; Fahimeh Ramezani Tehrani; Houshang Amirrasouli; Hooman Rahimi Pour; Mehdi Hedayati; Faranak Kazerouni; Adeleh Soltani
Journal:  Int J Endocrinol Metab       Date:  2014-07-01

4.  Serum visfatin levels in non-obese women with polycystic ovary syndrome and matched controls.

Authors:  Jin Ju Kim; Young Min Choi; Min A Hong; Min Jeong Kim; Soo Jin Chae; Sun Mie Kim; Kyu Ri Hwang; Sang Ho Yoon; Seung Yup Ku; Chang Suk Suh; Seok Hyun Kim
Journal:  Obstet Gynecol Sci       Date:  2018-02-05

Review 5.  Visfatin: A Possible Role in Cardiovasculo-Metabolic Disorders.

Authors:  Ali Dakroub; Suzanne A Nasser; Nour Younis; Humna Bhagani; Yusra Al-Dhaheri; Gianfranco Pintus; Assaad A Eid; Ahmed F El-Yazbi; Ali H Eid
Journal:  Cells       Date:  2020-11-09       Impact factor: 6.600

6.  Plasma visfatin levels and mRNA expression of visfatin in peripheral blood mononuclear cells and peripheral blood monocyte-derived macrophages from normal weight females with polycystic ovary syndrome.

Authors:  Jing Zhang; Lingling Zhou; Liulin Tang; Liangzhi Xu
Journal:  Exp Ther Med       Date:  2014-02-18       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.